SG10201811361XA - Treatment of polybacterials infections - Google Patents

Treatment of polybacterials infections

Info

Publication number
SG10201811361XA
SG10201811361XA SG10201811361XA SG10201811361XA SG10201811361XA SG 10201811361X A SG10201811361X A SG 10201811361XA SG 10201811361X A SG10201811361X A SG 10201811361XA SG 10201811361X A SG10201811361X A SG 10201811361XA SG 10201811361X A SG10201811361X A SG 10201811361XA
Authority
SG
Singapore
Prior art keywords
infections
polybacterial
antibody
specifically binds
pseudomonas aeruginosa
Prior art date
Application number
SG10201811361XA
Inventor
Bret Sellman
Jamese Hilliard
Omari Jones
Charles Stover
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of SG10201811361XA publication Critical patent/SG10201811361XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

ABSTRA CT Provided herein are me thods of preventing and treating polybacterial infections com prising administering an effective am ount of an antibody or antigen - binding fragment thereof that specifically binds to an epitope produced by a t least one of the bacterium in the polybacterial infection. For example, an antibody that specifically binds to Staphy lococcus aureus alpha toxin can be adm inistered to a patient with a polybacterial infection comprising Staphylococcus aureus and Pseudomonas aeruginosa to inhibit the growth of Pseudomonas aeruginosa. [F IG.]
SG10201811361XA 2014-06-19 2015-06-19 Treatment of polybacterials infections SG10201811361XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462014506P 2014-06-19 2014-06-19
US201562140849P 2015-03-31 2015-03-31

Publications (1)

Publication Number Publication Date
SG10201811361XA true SG10201811361XA (en) 2019-01-30

Family

ID=54936121

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201811361XA SG10201811361XA (en) 2014-06-19 2015-06-19 Treatment of polybacterials infections
SG11201609652RA SG11201609652RA (en) 2014-06-19 2015-06-19 Treatment of polybacterials infections

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201609652RA SG11201609652RA (en) 2014-06-19 2015-06-19 Treatment of polybacterials infections

Country Status (10)

Country Link
US (1) US11168132B2 (en)
EP (1) EP3157565B1 (en)
JP (2) JP6845016B2 (en)
KR (1) KR102549870B1 (en)
CN (1) CN106456767B (en)
AU (1) AU2015276938B2 (en)
CA (1) CA2952278A1 (en)
SG (2) SG10201811361XA (en)
TW (1) TWI719938B (en)
WO (1) WO2015196011A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012170807A2 (en) 2011-06-10 2012-12-13 Medimmune, Llc Anti-pseudomonas psl binding molecules and uses thereof
SI2776065T1 (en) 2011-11-07 2020-10-30 Medimmune Limited Combination therapies using anti- pseudomonas psl and pcrv binding molecules
SG11201503231YA (en) 2012-11-06 2015-05-28 Medimmune Llc METHODS OF TREATING <i>S. AUREUS</i>-ASSOCIATED DISEASES
SG11201503232TA (en) * 2012-11-06 2015-05-28 Medimmune Llc Antibodies to s. aureus surface determinants
JP7110095B2 (en) 2015-11-30 2022-08-01 メドイミューン・リミテッド How to prevent or treat nosocomial pneumonia
US20190153076A1 (en) * 2016-05-05 2019-05-23 The Trustees Of The University Of Pennsylvania DNA Antibody Constructs for Use against Pseudomonas Aeuruginosa
TW202311284A (en) 2017-01-03 2023-03-16 美商再生元醫藥公司 Human antibodies to s. aureus hemolysin a toxin
CA3107463A1 (en) 2018-07-24 2020-01-30 Medimmune, Llc Antibody directed against s. aureus clumping factor a (clfa)
TW202028232A (en) 2018-10-09 2020-08-01 美商麥迪紐有限責任公司 Antibodies directed against staphylococcus aureus leukotoxins
TW202035443A (en) 2018-10-09 2020-10-01 美商麥迪紐有限責任公司 Combinations of anti-staphylococcus aureus antibodies
GB201816554D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201816553D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
WO2021015237A1 (en) * 2019-07-24 2021-01-28 国立研究開発法人科学技術振興機構 Innovative production technique for antibody-enzyme
FR3114970B1 (en) 2020-10-08 2023-06-30 Univ Tours COMBINATION OF INHALED ANTIBODIES WITH IMMUNO-MODULATING AGENTS FOR THE TREATMENT OR PREVENTION OF RESPIRATORY INFECTIONS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2655133C (en) 2006-06-12 2018-03-20 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
US8642039B2 (en) * 2009-12-22 2014-02-04 Kalobios Pharmaceuticals, Inc. Method of treating a staphylococcus infection in a patient having a low-level pathogenic Pseudomonas aeruginosa infection
CA2826566C (en) * 2011-02-08 2022-09-13 Medimmune, Llc Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
SI2776065T1 (en) 2011-11-07 2020-10-30 Medimmune Limited Combination therapies using anti- pseudomonas psl and pcrv binding molecules
SG11201503231YA (en) 2012-11-06 2015-05-28 Medimmune Llc METHODS OF TREATING <i>S. AUREUS</i>-ASSOCIATED DISEASES
JP2015535005A (en) * 2012-11-06 2015-12-07 メディミューン，エルエルシー Combination therapy with anti-Pseudomonas Psl and PcrV binding molecules
SG11201503232TA (en) 2012-11-06 2015-05-28 Medimmune Llc Antibodies to s. aureus surface determinants
US20190077851A1 (en) 2015-10-30 2019-03-14 Bruno Francois Methods of using anti-alpha toxin antibody

Also Published As

Publication number Publication date
WO2015196011A1 (en) 2015-12-23
SG11201609652RA (en) 2016-12-29
JP2017519768A (en) 2017-07-20
KR20170015329A (en) 2017-02-08
EP3157565B1 (en) 2024-04-24
EP3157565A4 (en) 2018-03-21
KR102549870B1 (en) 2023-06-29
TW201613575A (en) 2016-04-16
AU2015276938A1 (en) 2017-01-05
CN106456767A (en) 2017-02-22
US20170129943A1 (en) 2017-05-11
EP3157565A1 (en) 2017-04-26
US11168132B2 (en) 2021-11-09
JP6845016B2 (en) 2021-03-17
JP2021063090A (en) 2021-04-22
AU2015276938B2 (en) 2020-11-19
TWI719938B (en) 2021-03-01
CN106456767B (en) 2021-07-09
CA2952278A1 (en) 2015-12-23

Similar Documents

Publication Publication Date Title
SG10201811361XA (en) Treatment of polybacterials infections
PH12018501429A1 (en) Compositions and methods for treating and preventing staphylococcus aureus infections
WO2017075188A3 (en) Methods of using anti-alpha toxin antibody
PH12016501577A1 (en) Monobactam organic compounds for the treatment of bacterial infections
MX2019007784A (en) Human antibodies to s. aureus hemolysin a toxin.
MX2019007613A (en) Combination therapy with amidine substituted ãŸ-lactam compounds and ãŸ-lactamase inhibitors for infections with antibiotic resistant bacterial strains.
MX2016007533A (en) Compositions and methods for phagocyte delivery of anti-staphylococcal agents.
MX363678B (en) Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections.
BR112017011478A2 (en) antibody-antibiotic conjugate compound, antibody-antibiotic conjugate, pharmaceutical composition, methods of treating a bacterial infection and exterminating staph aureus, process for compound preparation, kit and antibiotic-binder intermediate
PH12019500360A1 (en) Antibiotic compounds
MX2021002719A (en) Cannabinoids for the treatment of gram-positive infections including antibiotic-resistant bacterial strains.
WO2016142445A3 (en) Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection
EP3932917A3 (en) Substituted phenyloxazolidinones for antimicrobial therapy
ZA202002093B (en) Antibacterial compounds
MX2019011908A (en) Anti-bacterial peptide macrocycles and use thereof.
AU2012335397A8 (en) Novel bacteriophages
MX366894B (en) ANTIMICROBIAL COMPOSITIONS and METHODS FOR THEIR PRODUCTION.
WO2017137954A3 (en) Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
MX2018011095A (en) Carbapenem compounds.
AU2018257122A1 (en) Pharmaceutical composition comprising attenuated streptococcus pneumoniae strains and use thereof
WO2015100448A3 (en) Multimodal antimicrobial therapy
CO2021015337A2 (en) Methods and compositions comprising Staphylococcal protein a variants (spa)
BR112017022864A2 (en) antibacterial compositions
EA202290048A1 (en) MEDICINE AND ITS USE FOR THE TREATMENT OF BACTERIAL INFECTIONS ASSOCIATED WITH BIOFILM
WO2019025803A3 (en) An antimicrobial composition